Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

BACKGROUND: During the 2014 West African Ebola outbreak, Ebola vaccine development was accelerated. The phase 1 VAC52150EBL1003 study was performed to investigate 2-dose heterologous vaccination with Ad26.ZEBOV and MVA-BN-Filo in an African population located in a high-altitude setting in Nairobi, K...

Descripción completa

Detalles Bibliográficos
Autores principales: Mutua, Gaudensia, Anzala, Omu, Luhn, Kerstin, Robinson, Cynthia, Bockstal, Viki, Anumendem, Dickson, Douoguih, Macaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548899/
https://www.ncbi.nlm.nih.gov/pubmed/30796816
http://dx.doi.org/10.1093/infdis/jiz071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548899/
https://www.ncbi.nlm.nih.gov/pubmed/30796816
http://dx.doi.org/10.1093/infdis/jiz071

Ejemplares similares